Bio Roundup: Eli Lilly Tries Tau, Generic Insulin, NASH Cash & More
Xconomy
DECEMBER 14, 2018
Pharmaceutical industry critics lament the cost of rare disease drugs, but some of the steepest price hikes have come on widely used insulin. The patent holder, the University of Toronto, gave companies the right to manufacture insulin. to offer competitive pricing pressure. to offer competitive pricing pressure.
Let's personalize your content